PL2118309T3 - Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania - Google Patents
Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowaniaInfo
- Publication number
- PL2118309T3 PL2118309T3 PL07870089T PL07870089T PL2118309T3 PL 2118309 T3 PL2118309 T3 PL 2118309T3 PL 07870089 T PL07870089 T PL 07870089T PL 07870089 T PL07870089 T PL 07870089T PL 2118309 T3 PL2118309 T3 PL 2118309T3
- Authority
- PL
- Poland
- Prior art keywords
- diagnostic
- autoimmune diseases
- therapeutic target
- therapeutic
- target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rehabilitation Therapy (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88281506P | 2006-12-29 | 2006-12-29 | |
PCT/US2007/089125 WO2008083331A2 (en) | 2006-12-29 | 2007-12-28 | Diagnostic and therapeutic target for autoimmune diseases and uses thereof |
EP07870089.5A EP2118309B1 (en) | 2006-12-29 | 2007-12-28 | Diagnostic and therapeutic target for autoimmune diseases and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2118309T3 true PL2118309T3 (pl) | 2015-07-31 |
Family
ID=39589229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07870089T PL2118309T3 (pl) | 2006-12-29 | 2007-12-28 | Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania |
Country Status (8)
Country | Link |
---|---|
US (1) | US9023984B2 (pl) |
EP (1) | EP2118309B1 (pl) |
JP (1) | JP5694668B2 (pl) |
CN (1) | CN101646781B (pl) |
DK (1) | DK2118309T3 (pl) |
ES (1) | ES2533566T3 (pl) |
PL (1) | PL2118309T3 (pl) |
WO (1) | WO2008083331A2 (pl) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011034539A1 (en) * | 2009-09-18 | 2011-03-24 | The Regents Of The University Of California | Methods for detecting autodigestion |
CN102060910B (zh) * | 2010-11-12 | 2012-11-21 | 中国人民解放军第三军医大学 | 锌转运蛋白8的hla-a*0201限制性ctl表位及其应用 |
WO2012149259A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce antibody responses |
US20140271701A1 (en) | 2011-10-26 | 2014-09-18 | Universita' Degli Studi Di Sassari | Use of mycobacterium avium paratuberculosis peptides to diagnose type 1 diabetes |
CN103177198B (zh) * | 2011-12-26 | 2016-11-23 | 深圳华大基因科技服务有限公司 | 一种蛋白质鉴定方法 |
US8852873B2 (en) | 2012-04-13 | 2014-10-07 | Diabetomics, Llc | Maternal biomarkers for gestational diabetes |
CN102967704B (zh) * | 2012-11-26 | 2014-05-14 | 深圳市伯劳特生物制品有限公司 | 一种用于糖尿病自身抗体6项联检试剂盒 |
WO2014160175A1 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Plasmonic substrate for multiplex assessment of type 1 diabetes |
EA201592103A3 (ru) | 2013-05-03 | 2016-08-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для усиления cd4+ регуляторных t-клеток |
KR102205234B1 (ko) | 2013-06-11 | 2021-01-20 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | SC-β 세포 및 조성물 그리고 그 생성 방법 |
RU2019129803A (ru) * | 2014-06-04 | 2020-12-14 | Диамид Медикал Аб | Новые комбинации для антигенной терапии |
KR101482908B1 (ko) | 2014-07-25 | 2015-01-15 | 충남대학교산학협력단 | 간질중첩증 진단용 바이오마커 조성물 |
CN106714826A (zh) | 2014-09-07 | 2017-05-24 | 西莱克塔生物科技公司 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
CN107614678B (zh) | 2014-12-18 | 2021-04-30 | 哈佛学院校长同事会 | 干细胞来源的β细胞的产生方法及其使用方法 |
DK3234110T3 (da) | 2014-12-18 | 2024-05-13 | Harvard College | FREMGANGSMÅDER TIL GENERERING AF STAMCELLE-AFLEDTE ß-CELLER OG ANVENDELSER DERAF |
US10443042B2 (en) | 2014-12-18 | 2019-10-15 | President And Fellows Of Harvard College | Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof |
GB201510056D0 (en) * | 2015-06-10 | 2015-07-22 | King S College London | Multi-peptide composition |
US10542961B2 (en) | 2015-06-15 | 2020-01-28 | The Research Foundation For The State University Of New York | System and method for infrasonic cardiac monitoring |
CN106084051B (zh) * | 2016-02-17 | 2018-03-02 | 张梅 | 一种ZnT8特异性单链抗体scFv‑C27及其应用 |
CN106084043B (zh) * | 2016-02-17 | 2018-03-02 | 张梅 | 一种ZnT8特异性单链抗体scFv‑C22及其应用 |
US11016085B2 (en) | 2016-04-25 | 2021-05-25 | The Johns Hopkins University | ZNT8 assays for drug development and pharmaceutical compositions |
CN106771233A (zh) * | 2016-12-05 | 2017-05-31 | 上海良润生物医药科技有限公司 | ZnT8A自身抗体检测试剂盒 |
CN110612122A (zh) | 2017-03-11 | 2019-12-24 | 西莱克塔生物科技公司 | 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物 |
US11892457B2 (en) | 2017-07-12 | 2024-02-06 | The Johns Hopkins University | Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis |
IL274436B2 (en) | 2017-11-15 | 2024-01-01 | Semma Therapeutics Inc | Preparations for the production of islet cells and methods of use |
CN108414766A (zh) * | 2018-01-29 | 2018-08-17 | 上海良润生物医药科技有限公司 | 用于定量检测糖尿病自身抗体的试剂盒及其应用 |
EP3833365A4 (en) | 2018-08-10 | 2022-05-11 | Vertex Pharmaceuticals Incorporated | ISLE DIFFERENTIATION DERIVED FROM STEM CELLS |
CN109628462B (zh) * | 2018-12-13 | 2021-02-19 | 宁波大学 | 一种水稻根系伸长控制基因OsKSR7及编码的蛋白质 |
CN109734793B (zh) * | 2019-03-14 | 2022-12-02 | 深圳市药品检验研究院(深圳市医疗器械检测中心) | 一种ZnT8重组蛋白及其制备方法和应用 |
CN111579791A (zh) * | 2020-04-30 | 2020-08-25 | 江苏省人民医院(南京医科大学第一附属医院) | 一种锌转运体8胰岛自身抗体的电化学发光检测试剂盒 |
CN113999841A (zh) * | 2021-09-16 | 2022-02-01 | 江苏省人民医院(南京医科大学第一附属医院) | 蛋白质支架oval100及其在放射配体法中的应用 |
CN117031014A (zh) * | 2023-08-14 | 2023-11-10 | 陕西脉元生物科技有限公司 | 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
CA2043472A1 (en) | 1990-06-04 | 1991-12-05 | Mitsutaka Miyabayashi | Electrode for secondary battery |
US5820866A (en) | 1994-03-04 | 1998-10-13 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for T cell regulation |
WO2001094409A2 (en) | 2000-06-07 | 2001-12-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
FR2847263B1 (fr) * | 2002-11-18 | 2006-01-13 | Commissariat Energie Atomique | Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans |
-
2007
- 2007-12-28 WO PCT/US2007/089125 patent/WO2008083331A2/en active Application Filing
- 2007-12-28 PL PL07870089T patent/PL2118309T3/pl unknown
- 2007-12-28 EP EP07870089.5A patent/EP2118309B1/en active Active
- 2007-12-28 DK DK07870089T patent/DK2118309T3/en active
- 2007-12-28 JP JP2009544308A patent/JP5694668B2/ja active Active
- 2007-12-28 US US12/521,022 patent/US9023984B2/en active Active
- 2007-12-28 ES ES07870089.5T patent/ES2533566T3/es active Active
- 2007-12-28 CN CN200780051859.3A patent/CN101646781B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN101646781A (zh) | 2010-02-10 |
DK2118309T3 (en) | 2015-03-30 |
EP2118309B1 (en) | 2015-01-28 |
ES2533566T3 (es) | 2015-04-13 |
US9023984B2 (en) | 2015-05-05 |
JP5694668B2 (ja) | 2015-04-01 |
US20100143374A1 (en) | 2010-06-10 |
JP2010514805A (ja) | 2010-05-06 |
EP2118309A2 (en) | 2009-11-18 |
EP2118309A4 (en) | 2010-06-02 |
WO2008083331A3 (en) | 2008-11-13 |
WO2008083331A2 (en) | 2008-07-10 |
CN101646781B (zh) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2118309T3 (pl) | Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania | |
IL195052A0 (en) | Patient customized therapeutic regimens | |
EP1993528A4 (en) | TREATMENT MODULES FOR AUTOIMMUNE DISEASES | |
EP2076198A4 (en) | Inducing Desired Temperatreating Effects on Body Weave | |
EP2119444A4 (en) | THERAPEUTIC AGENT FOR PAIN | |
GB0602178D0 (en) | Therapeutic treatment | |
PL2056842T3 (pl) | Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych | |
EP2068864A4 (en) | THERAPEUTIC USES OF UROLITHINS | |
EP2004230A4 (en) | N-CADHERIN AND LY6 E: TARGETS FOR DIAGNOSIS AND TREATMENT OF CANCER | |
GB0608655D0 (en) | Therapeutic Treatment | |
GB0722996D0 (en) | Depsipeptides and their therapeutic use | |
EP1974055A4 (en) | DIAGNOSTIC AND THERAPEUTIC OBJECTIVES AGAINST LEUKEMIA | |
IL192415A0 (en) | Pharmaceutical composition for the treatment of nail diseases | |
IL212800A0 (en) | N-cadherin: target for cancer diagnosis and therapy | |
GB2457640B (en) | Body armour | |
EP2097093A4 (en) | THERAPEUTIC AND DIAGNOSTIC PEPTIDES | |
EP1976426A4 (en) | SYSTEM AND METHODS FOR MEDICAL DIAGNOSIS | |
GB0610909D0 (en) | Therapeutic treatment | |
GB0700645D0 (en) | Targets for disease therapy | |
EP2059238A4 (en) | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | |
EP2127658A4 (en) | THERAPEUTIC AGENT AGAINST MORBUS MENIERE | |
EP2215270A4 (en) | DIAGNOSIS AND THERAPY REQUIREMENTS | |
GB0621308D0 (en) | An implement for administering medicine | |
GB0610376D0 (en) | Therapeutic treatment | |
GB0614538D0 (en) | Therapeutic Compounds And Their Use |